Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
GENE Stock — Genetic Technologies Ltd
Genetic Technologies Ltd (GENE)
Updated October 16, 2026.
GENE is a Stock. Total return is 67.9% over the past 21.1 years, 741.6 points behind SPY at 809.5%.
Genetic Technologies Limited is a molecular diagnostics company that develops and markets predictive genetic testing and risk assessment tools for cancer and other diseases. The company operates testing services under brands including BREVAGenplus for breast cancer risk assessment, GeneType for colorectal and breast cancer, and various other disease-specific tests, serving healthcare providers globally through segments including EasyDNA and AffinityDNA. The company does not currently have an established distribution schedule.
GENE dividend yield and income
Price as of 2026-10-16.
The payment date is 08/15/2019.
GENE performance versus SPY
Price and return data through 2026-10-16.
Total return is 67.9% over the past 21.1 years, 741.6 points behind SPY at 809.5%. Over the past year its total return — price change plus distributions reinvested — is 14.6%. Its deepest 1-year drawdown was 6.8%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | 2.0% | — |
| 3M | 2.3% | — |
| 6M | 4.9% | — |
| YTD | 9.5% | — |
| 1Y | 14.6% | — |
| 2Y CAGR | — | 5029.70% |
| 3Y CAGR | — | 731.50% |
| 5Y CAGR | — | 166.00% |
| 10Y CAGR | — | 50.80% |
| Since inception (21.1 years) | 67.9% | 2.50% |
GENE key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 09/06/2005
- Distribution frequency
- None
- Last close
- $2,015.25 (as of 2026-10-16)
- Market cap
- $9,768,400,410
- Average volume
- 39.0
- Payment date
- 08/15/2019
- Beta
- 0.48
- Payout ratio
- 0.0%
- EPS
- $-0.02
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
GENE risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 6.8%.
Who may consider GENE — and who may not
It is a weaker fit for investors who need monthly cash flow (GENE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on GENE
Frequently asked questions
Does GENE pay monthly?
No. GENE does not currently distribute.
When does GENE pay a dividend?
GENE does not currently distribute. The payment date is 08/15/2019.
How has GENE performed?
Total return is 67.9% over the past 21.1 years, 741.6 points behind SPY at 809.5%. Over the past year its total return — price change plus distributions reinvested — is 14.6%. Its deepest 1-year drawdown was 6.8%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.